Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension (Q35696476)

9 August 2017

1 reference

title

Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension (English)

1 reference

9 August 2017

1 reference

Bernard Waeber

1

1 reference

9 August 2017

publication date

1 May 2003

1 reference

Expert Review of Cardiovascular Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

1

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

43-50

1 reference

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Diastolic pressure, systolic pressure, or pulse pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Pharmacoeconomics of hypertension management: the place of combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

The control of renin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Reciprocal relation between renin dependency and sodium dependency in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.43

21 January 2018

Identifiers

DOI

10.1586/14779072.1.1.43

1 reference

9 August 2017

1 reference